The incidence, risk, and consequences of atrial arrhythmias in patients with continuous-flow left ventricular assist devices

Journal of Cardiac Surgery

Volumn 29, Issue 4, 2014, Pages 572-580

  Brisco, Meredith A ^a   Sundareswaran, Kartik S ^b   Milano, Carmelo A ^c   Feldman, David ^d   Testani, Jeffrey M ^e   Ewald, Gregory A ^f   Slaughter, Mark S ^g   Farrar, David J ^b   Goldberg, Lee R ^h  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b THORATEC CORPORATION   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BARNES JEWISH HOSPITAL   (United States)

^g UNIVERSITY OF LOUISVILLE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DOFETILIDE; MAGNESIUM; POTASSIUM; SOTALOL; CREATININE;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CLINICAL TRIAL (TOPIC); CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; HAZARD RATIO; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; INTRAAORTIC BALLOON PUMP; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POST HOC ANALYSIS; PREOPERATIVE PERIOD; QUALITY OF LIFE; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; AGED; ARRHYTHMIAS, CARDIAC; BLOOD; CLINICAL TRIAL; HEART ASSIST DEVICE; HEART ATRIUM; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; TIME;

AGED; ARRHYTHMIAS, CARDIAC; CREATININE; FEMALE; HEART ATRIA; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RISK; RISK FACTORS; TIME FACTORS;

EID: 84904066068     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/jocs.12336     Document Type: Article

References (35)

1. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. Studies of left ventricular dysfunction. J Am Coll Cardiol 1998; 32: 695-703. (Pubitemid 28435256)
2. Benjamin EJ, Wolf PA, D'agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation 1998; 98: 946-952. (Pubitemid 28446646)
3. Maisel WH, Stevenson LW:, Atrial fibrillation in heart failure: Epidemiology. pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D. (Pubitemid 36369329)
4. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence. incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998; 82: 2N-9N. (Pubitemid 28507114)
5. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med 1991; 325: 293-302.
6. Van Den Berg MP, Tuinenburg AE, Crijns HJ, et al. Heart failure and atrial fibrillation: Current concepts and controversies. Heart 1997; 77: 309-313. (Pubitemid 27208168)
7. Solti F, Vecsey T, Kekesi V, et al. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res 1989; 23: 882-886. (Pubitemid 19269865)
8. Pardaens K, Van Cleemput J, Vanhaecke J, et al. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997; 78: 564-568. (Pubitemid 28034204)
9. Levy T, Walker S, Mason M, et al. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: A randomised controlled study. Heart 2001; 85: 171-178. (Pubitemid 32973588)
10. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
11. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357: 885-896. (Pubitemid 47347322)
12. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 2010; 55: 1826-1834.
13. James KB, Mccarthy PM, Thomas JD, et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 1995; 92: 191-195.
14. Klotz S, Jan Danser AH, Burkhoff D., Impact of left ventricular assist device (LVAD) support on the cardiac reverse remodeling process. Prog Biophys Mol Biol 2008; 97: 479-496.
15. Drakos SG, Terrovitis JV, Nanas JN, et al. Reverse electrophysiologic remodeling after cardiac mechanical unloading for end-stage nonischemic cardiomyopathy. Ann Thorac Surg 2011; 91: 764-769.
16. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010; 29: S1-S39.
17. Ascione R, Caputo M, Calori G, et al. Predictors of atrial fibrillation after conventional and beating heart coronary surgery: A prospective, randomized study. Circulation 2000; 102: 1530-1535.
18. Brasil LA, Gomes WJ, Salomão R, et al. Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 56-59. (Pubitemid 28389230)
19. Lo LW, Tai CT, Lin YJ, et al. Predicting factors for atrial fibrillation acute termination during catheter ablation procedures: Implications for catheter ablation strategy and long-term outcome. Heart Rhythm 2009; 6: 311-318.
20. El-Chami MF, Kilgo P, Thourani V, et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol 2010; 55: 1370-1376.
21. Iguchi Y, Kimura K, Kobayashi K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102: 1056-1059.
22. Nisanoglu V, Erdil N, Aldemir M, et al. Atrial fibrillation after coronary artery bypass grafting in elderly patients: Incidence and risk factor analysis. Thorac Cardiovasc Surg 2007; 55: 32-38. (Pubitemid 47234086)
23. Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010; 28: 1738-1744.
24. Testani JM, Coca SG, Shannon RP, et al. Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: Analysis of three randomized controlled trials. Eur J Heart Fail 2011; 13: 1224-1230.
25. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999; 100: 87-95. (Pubitemid 29297945)
26. Groenveld HF, Crijns HJ, Van Den Berg MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: Data from the RACE II (rate control efficacy in permanent atrial fibrillation ii) study. J Am F Coll Cardiol 2011; 58: 1795-1803.
27. Wokhlu A, Monahan KH, Hodge DO, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol 2010; 55: 2308-2316.
28. Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: A Veterans Affairs cooperative studies program substudy. J Am Coll Cardiol 2006; 48: 721-730. (Pubitemid 44175705)
29. Ahmed S, Ranchor AV, Crijns HJ, et al. Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. Europace 2010; 12: 785-791.
30. Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008; 359: 999-1008.
31. Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence. risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010; 139: 1316-1324.
32. Aziz EF, Kukin M, Javed F, et al. Right ventricular dysfunction is a strong predictor of developing atrial fibrillation in acutely decompensated heart failure patients, ACAP-HF data analysis. J Card Fail 2010; 16: 827-834.
33. Stiles MK, John B, Wong CX, et al. Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: Characterizing the "second factor." J Am Coll Cardiol 2009; 53: 1182-1191.
34. Akutsu Y, Kaneko K, Kodama Y, et al. Association between left and right atrial remodeling with atrial fibrillation recurrence after pulmonary vein catheter ablation in patients with paroxysmal atrial fibrillation: A pilot study. Circ Cardiovasc Imaging 2011; 4: 524-531.
35. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: Analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009; 28: 881-887.